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Results
We identified 13 conditions from the IMM list that could 
be associated with dysregulated immunity during 
spaceflight. Table 1 reflects the incidence of the original 
13 IMM conditions, while Table 2 shows the symptoms 
and conditions in this telemedicine environment.
Conclusions
Using signs and symptoms reported via telemedicine 
and documented within patient medical records, we 
conducted a retrospective review and analysis. This 
approach has improved epidemiologists’ ability to 
provide summary evidence regarding incidence of 
potential inflight medical conditions. These results inform 
our NASA physicians and researchers and support 
evaluation of the occupational health risks associated 
with spaceflight. 
Limitations
In the absence of a definitive resolution date or 
recurrence status by the physician, the criteria could be 
biased towards a higher frequency score.
Introduction
Space medicine presents unique challenges and 
opportunities for epidemiologists, such as the use of 
telemedicine during spaceflight. Medical capabilities 
aboard the International Space Station (ISS) are 
limited due to severe restrictions on power, volume, 
and mass. Consequently, inflight health information 
is based heavily on crewmember (CM) self-report of 
signs and symptoms, rather than formal diagnoses. 
While CM’s are in flight, the primary source of crew 
health information is verbal communication between 
physicians and crewmembers. 
In 2010 NASA implemented the Lifetime 
Surveillance of Astronaut Health, an occupational 
surveillance program for the U.S. Astronaut corps. 
This has shifted the epidemiological paradigm from 
tracking diagnoses based on traditional terrestrial 
clinical practice to one that incorporates 
symptomatology and may gain a more population-
based understanding of early detection of disease 
process. 
Methods
The study population was 37 NASA astronauts who 
flew on the ISS for Expeditions 1 – 28/29 (10/31/00–
11/22/11). This represents 6,112 total days in space 
and 16.75 person-years. If an astronaut had more 
than one ISS flight during this timeframe, each 
mission was counted separately, resulting in 37 
person-missions (28 men and 9 women).
The NASA Integrated Medical Model (IMM) is an 
operational tool that helps align science, technology, 
and operational activities. The IMM is used to 
optimize crew health and safety and ensure mission 
success by quantifying the probability and 
consequences of medical risks. IMM identified 100 
medical conditions that may result in crewmember 
impairment, of which we identified 13 that may be 
associated with immune dysregulation (Table 1). 
Events such as congestion, nausea, diarrhea or 
constipation that were reported and resolved within the 
first 30 days of flight were classified as due to space 
adaptation rather than immune dysregulation and were 
therefore excluded. 
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Table 1: IMM Conditions (Expeditions 1 – 28/29 )
Medical Conditions Total 
Events
Event / Flight
Year
Allergic Reaction 1 0.1
Anaphylaxis 0 -
Upper Respiratory 
Infection
0 -
Eye Infection 0 -
Herpes Zoster  0 -
Otitis Externa 0 -
Otitis Media 1 0.1
Pharyngitis 1 0.1
Sepsis 0 -
Sinus Infection 0 -
Skin Infection 3 0.1
Skin Rash 6 0.3
Urinary Tract Infection 0 -
Total 12 0.7
Table 2: Symptoms and Conditions  
Expeditions 1 – 28/29, N= 37  U.S. Crewmembers only
Medical Conditions and Symptoms Total Events Event / Flight Year
Allergic Reaction (Hypersensitivity) 2 0.1
Prolonged Congestion, Rhinitis, Sneezing 11 0.7
Herpesviruses (cold sores) 6 0.3
Ear Related Symptoms: Pain, Congestion, Itchiness 4 0.2
Pharyngitis (Sore throat) 1 0.1
Skin Infection (including pus forming wounds) 5 0.3
Skin Rash/Hypersensitivity (including skin conditions such as tinea versicolor, 
dermatitis, rosacea)
21 1.2
Urinary Tract Infection and/or symptoms 2 0.1
Infections and Other related symptoms (including fever, aphthous ulcer, 
lymphadenitis)
4 0.2
Total 56 3.3
6112 total days in space, 16.75 person - years
To evaluate additional indicators associated with immune 
precursors, we reviewed and expanded the IMM list to 
include signs and symptoms reported by crewmembers 
(Table 2). We reviewed all available sources of information 
including clinical records, Space Medicine Operations Team 
(SMOT) meeting minutes, a past integrated immune study 
survey, and postflight research debriefings. 
Some overlap between categories was possible, depending 
on the specific symptoms. For all such instances, the 
epidemiologist and immunologist evaluators selected the 
single most appropriate category based on the event signs 
and symptoms reported. Events were not double-scored and 
we did not infer recurrence. If an event was noted as 
resolved by the flight surgeon or had a specific end date 
noted, and then a similar event occurred later in the mission, 
the events were tabulated as separate events. Observable 
symptom-events with causes other than immune 
dysregulation, such as intestinal complaints due to food, 
abrasions, or eye irritations/tearing were not included in this 
evaluation. 
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